Jun 24 |
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS
|
May 28 |
EDSA: Preparing IND for Phase 2 Trial of EB06 in Vitiligo
|
May 10 |
Edesa Biotech GAAP EPS of -$0.58 beats by $0.11
|
May 10 |
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results
|
Apr 11 |
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
|
Apr 2 |
Edesa Biotech to Participate in Upcoming Investor Conferences
|
Mar 21 |
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
|
Mar 7 |
Edesa Biotech to Participate in Barclays Global Healthcare Conference
|
Feb 15 |
EDSA: Development of EB05 in ARDS Continues…
|
Feb 9 |
Edesa Biotech GAAP EPS of -$0.54 beats by $0.67
|